Mainz Biomed N.V. (QUCY)

Mainz Biomed N.V. (QUCY) — VMCI valuation read

QUCY prints VMCI 36/100 inside the Healthcare sector, where the median sits at 50. The 14-point below-median delta is the cleanest single-number summary of Mainz Biomed N.V.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On QUCY, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** QUCY trades at 20.0x earnings, 11% above the Healthcare median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 2.1x is the rate-sensitivity line to watch; that is the risk line for Mainz Biomed N.V. on the trailing financials.

QUCY fell 0.4% over the trailing 7 days, with a -13.5% read on a 30-day basis.